Choose less-stripped dairy for MFGM

For the July 6 weekly window, the strongest non-duplicate nutrition paper is a new systematic review and meta-analysis in Advances in Nutrition on milk fat globule membrane, or MFGM, and milk polar lipids. 1 The practical decision is narrow: if dairy already fits your diet, do not assume skim or highly stripped dairy is always the better cardiometabolic choice.

Borkar and colleagues pooled 13 randomized controlled trials, reported across 14 articles, in disease-free adults. The trials compared bovine-derived MFGM or milk polar lipids with isoenergetic dairy products or supplements that were low in those components. Intake lasted 2 to 16 weeks, and daily dose ranged from 19.8 mg to 5,000 mg. 1

The lipid signal was consistent. MFGM or milk polar lipids reduced fasting total cholesterol by 0.18 mmol/L, or about 6.9 mg/dL; LDL cholesterol by 0.12 mmol/L, or about 4.6 mg/dL; apolipoprotein B by 0.05 g/L; and the total cholesterol-to-HDL ratio by 0.17. Heterogeneity was low, with I² between 0% and 9%, and the authors rated certainty for these lipid outcomes as moderate. 1

That is not a drug-sized LDL reduction. It is closer to a small dietary nudge. The same paper found no clear effect on fasting HDL cholesterol, triglycerides, glucose, insulin, or blood pressure, and the certainty for those outcomes was low. Evidence for cognitive outcomes and post-meal responses was too limited for a firm conclusion. 1

MFGM is the natural membrane around milk fat globules. It includes polar lipids and membrane proteins that may change how dairy fat behaves in digestion and metabolism. 2 That matters because common dairy advice often treats fat content as the main variable.

Processing changes the membrane. The University of Guelph dairy science text explains that homogenization reduces milk fat globule diameter from about 3.3 micrometers to 0.4 micrometers and increases surface area from 0.08 to 0.75 m²/mL. During that process, the native MFGM is lost and replaced by casein micelles and whey proteins from the milk plasma. 3

Skimming changes the equation more directly because removing milk fat also removes the fat globules that carry MFGM. The Loughborough University release on the Borkar review describes milk lipid bioactives as naturally occurring dairy-fat components that are particularly abundant in cream and buttermilk, and that can also be concentrated into specialized dairy ingredients. 4

The same-day translation is therefore not "eat more butter." The safer move is this: when choosing dairy, favor unsweetened products that keep more of the dairy matrix intact, such as plain whole-milk yogurt, kefir, cheese in modest portions, or buttermilk, instead of treating skim milk or low-fat sweetened dairy as the automatic heart-health default.

For a generally healthy adult who already eats dairy, this evidence supports a swap, not an add-on. A reasonable same-day choice is to replace one low-MFGM dairy item with an unsweetened, less-stripped option and keep the portion normal. Examples include plain whole-milk yogurt instead of a sweetened low-fat yogurt, buttermilk as a cultured dairy option, or a modest portion of cheese instead of a butter-heavy food.

The distinction matters. MFGM appears most relevant when it displaces a lower-MFGM comparator under similar energy conditions. The meta-analysis compared MFGM or milk-polar-lipid products with isoenergetic dairy products or supplements low in those components. 1 Adding cream or butter on top of an unchanged diet is a different question, and this review does not show that doing so improves risk.

Dietitians can translate the finding more precisely: for clients who tolerate dairy, have no need to avoid dairy fat, and are choosing between otherwise similar dairy foods, MFGM content is a reason not to make fat removal the only criterion. For clients with high LDL cholesterol, familial hypercholesterolemia, established cardiovascular disease, or a saturated-fat target, this paper is not a reason to override individualized lipid management.

The review is stronger than a single trial because it pooled RCTs and found low heterogeneity for the main lipid outcomes. It is still short-term evidence. The included interventions lasted 2 to 16 weeks, and the abstract does not provide a total participant count or enough detail to compare individual food forms, doses, or populations trial by trial. 1

Conflict-of-interest context also matters. The PubMed record states that corresponding author Oonagh Markey has received related research funding from Arla Foods Ingredients Group P/S to support Aishwarya Borkar's doctoral research, while noting that Arla Foods Ingredients did not fund or provide input into this systematic review and meta-analysis. The second author declared no competing interests. 1

Guidelines are not settled around this mechanism. The American Heart Association responded to the 2025-2030 Dietary Guidelines for Americans by encouraging low-fat and fat-free dairy products, while the World Health Organization continues to recommend reduced-fat dairy foods and keeping saturated fat below 10% of energy. 5 6 MFGM is a useful biological detail, but it has not yet become a formal dietary guideline category.

The most defensible takeaway is modest. MFGM-rich dairy may slightly improve atherogenic lipid markers compared with low-MFGM dairy comparators. If dairy is already on the menu, choose the less stripped, unsweetened version more often. Do not use this paper as permission to add extra saturated-fat calories or to expect medication-scale LDL lowering.